Rayhan Lal, MD
Endocrinology, Diabetes & Metabolism · Stanford, CANPI 1083846166
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,433 of the $27,552 with a category attached, or 88.7%. Abbott accounts for 67.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $10,939 and has fallen 94.4% since, to $613 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $888.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$19K
- Eli Lilly$6K
- Sanofi-aventis U.S. LLC$1K
- Intuitive Surgical$800
- Tandem Diabetes Care, Inc.$409
- Dexcom, Inc.$262
- plus $618 from 5 others
Across 55 payments — averaging $12,613 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$649K
- Insulet Corporation$44K
What the payments were for
- Consulting fees$24,43389%
- Travel & lodging$6893%
- Food & beverage$1,6306%
- Education$8003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $18,709 |
| Eli Lilly | 4 | $5,689 |
| Sanofi-aventis U.S. LLC | 2 | $1,065 |
| Intuitive Surgical | 2 | $800 |
| Tandem Diabetes Care, Inc. | 4 | $409 |
| Dexcom, Inc. | 2 | $262 |
| Sequel Med Tech, LLC | 3 | $233 |
| Medtronic(2 entities) | 3 | $126 |
| Senseonics, Incorporated | 1 | $123 |
| Novo Nordisk | 1 | $123 |
| Mannkind Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre$13,338
- FreeStyle Libre Pro$5,250
- Da Vinci Surgical System$800
- t:slim X2 Insulin Pump with Control-IQ$211
- TZIELD$170
- TWIIST$161
- DEXCOM G6 TRANSMITTER$153
- t-slim insulin pump$139
- Eversense$123
- Ozempic$123
- FREESTYLE LIBRE 3$121
- DEXCOM CGM$109
How this compares
$27,552 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 12 | $102 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Stanford
- Andrew HoffmanStanford$63K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.